XmAb 13676

Drug Profile

XmAb 13676

Alternative Names: XmAb®13676

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Xencor
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD20 antigen modulators; CD3 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I B cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 02 Nov 2016 Xencor plans a phase I trial for B-cell lymphoma
  • 01 Oct 2016 Phase-I clinical trials in B-cell lymphoma in USA (Parenteral) (NCT02924402)
  • 01 Oct 2016 Phase-I clinical trials in Chronic lymphocytic leukaemia in USA (Parenteral) (NCT02924402)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top